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ABSTRACT 
Tyrosine kinase inhibitors (TKIs) blocking the BCR-ABL1 oncokinase activity have 
led to a revolutionary progress in the treatment and prognosis of chronic myeloid 
leukemia (CML). Nevertheless, a small fraction of patients still does not respond 
satisfactorily to TKI treatment. Therefore, early prediction of treatment response 
remains one of the major research focuses in order to perform timely treatment 
modifications.  
First, in study I, we involved 52 patients with chronic-phase (CP) CML who used 
first-line TKIs (imatinib, nilotinib, and dasatinib) for treatment. We used the fold 
change (FC) in BCR-ABL1 levels between diagnosis (dg) and 1 month as an 
indicator for early response to treatment. After 1 month of TKI therapy, we 
identified a poor responders patient group with an inferior long term response. 
Poor responders did not show any decline in BCR-ABL1 levels during the first 
month of therapy. Biologically, they were a distinct subgroup with enlarged spleens 
and a higher Ph+CD34+CD38- stem cell burden at dg.  
Secondly, in study II, we studied the bone marrow (BM) lymphocytosis 
phenomenon occurring during TKI therapy. We involved 105 CP CML patients on 
first-line TKIs (imatinib, dasatinib, and nilotinib) to assess BM lymphocytes by 
morphology through counting from slides stained by the May-Grünwald-Giemsa 
(MGG) method and immunophenotyping by flow cytometry. Our results 
demonstrated that all current TKIs used as first-line treatment in CML induced BM 
lymphocytosis, which was associated with a better treatment response, as a higher 
proportion of patients with increased BM lymphocyte counts achieved a 3-month 
molecular response of BCR-ABL1 transcript levels being less than 10%. However, 
lymphocytosis occurred in peripheral blood (PB) only during dasatinib therapy. 
13 
 
Study III examined hypogammaglobulinemia and the effects of TKI therapy 
(imatinib, dasatinib, nilotinib, and bosutinib) on B cells. We collected BM and PB 
samples from 56 first–line TKI treated CP CML patient and found that imatinib 
treatment decreased IgA and IgG levels, while dasatinib patients had decreased 
IgM levels. Importantly, we found that an initial decrease in Ig levels at dg 
predisposed the patient to hypogammaglobulinemia during TKI therapy. 
Hypogammaglobulinemia was associated only with mild infections, and no severe 
infections were reported. 
In conclusion, this thesis demonstrates that after 1 month of TKI therapy, it is 
already possible to identify the patients who will have inferior long-term 
responses. Furthermore, TKI treatment induces immunological effects, such as 
BM lymphocytosis, which are related to therapy responses. In addition to effects on 
T cells, the B cell compartment is also affected, which can be observed as 
hypogammaglobulinemia during the treatment. As CML patients are using TKI 
therapy for years or even decades, immunological monitoring during the course of 
therapy is warranted. 
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INTRODUCTION  
Chronic myeloid leukemia (CML) is a malignant hematological disease caused by 
a translocation between chromosomes 9 and 22, resulting in the pathological 
Philadelphia chromosome (Ph) represented by the BCR-ABL1 oncogene. The 
disease is composed of three phases: chronic phase (CP), accelerated phase (AP), 
and blast crisis (BC) (Table 1). A revolutionary change in CML treatment occurred 
with the discovery of tyrosine kinase inhibitors (TKIs). Currently, TKIs are the 
golden standard for the treatment of CML. Imatinib was the first TKI to be 
discovered, and now there are several second-generation TKIs available, including 
dasatinib, nilotinib, and bosutinib. The current aim of the treatment is first to 
achieve a major molecular response (MMR), in which BCR-ABL1 transcript levels 
are less than 0.1%. After achieving MMR, deeper molecular responses (such as 
MR4 and MR4.5, Table 3) are pursued, and TKI treatment can be stopped if the 
patient has been in remission for a long period of time. 
Finding methods for the early prediction of treatment outcomes in CP CML is a 
clinical research focus. Treatment outcomes are dependent on whether the patients 
will achieve satisfactory molecular responses (MR). Poor responses implement 
treatment modifications to prevent an undesirable progression of the disease. 
In addition to the main effect of TKIs on BCR-ABL1 inhibition, they also have 
secondary effects on the immune system. For example, it has been shown that 
dasatinib treatment is associated with an increase in large granular lymphocyte 
(LGL) cells. 
In this study, the early effects of TKIs, both the primary effect on BCR-ABL1 
transcript levels as well as the secondary effects on the immune system, were 
investigated. The aim was to identify patients with good and inferior responses to 
15 
 
TKI therapy, and to analyze how changes in the immune system influence the 
overall therapy outcome.   
16 
 
REVIEW OF THE LITERATURE 
1. Chronic myeloid leukemia (CML), an overview 
Myeloproliferative diseases, also called myeloproliferative neoplasms (MPNs), are 
a group of hematological disease in which there are defects in the myeloid cell 
lineage at various developmental stages. There are several types of 
myeloproliferative diseases, including CML, essential thrombocythemia, 
polycythemia vera, primary myelofibrosis, chronic neutrophilic leukemia, and 
mastocytosis. In general, the other MPNs are classified as Ph negative diseases to 
separate them from CML.  However, there is atypical Ph negative CML.1,2 
CML is classified as chronic phase CML (CP CML), accelerated phase CML (AP 
CML), and blast crisis CML (BC CML). Patients are commonly diagnosed with CP 
CML, which is characterized as being hypercellular with normal or slightly 
immature myeloid cellular maturation. Consequently, a minimal number of blasts 
are found in the peripheral blood (PB) cells and/or bone marrow (BM); the 
maximum number of blasts is 9%. If left untreated, CP CML can progress to AP 
CML or BC CML within 4 years. AP CML is characterized by an increased blast 
percentage in PB cells or BM. The characteristics of AP CML and BC CML are 
based on World Health Organization (WHO) criteria, as shown in Table 1.1,3–5  
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Table 1. AP CML and BC CML characteristics according to WHO.3 
AP CML* BC CML* 
Blasts are 10–19% in PB or BM Blasts are ≥20% in PB or BM 
Any of the following are persistent 
and nonresponsive to treatment: 
#WBC > 10 x109/l(persistent) 
#Splenomegaly (persistent or 
increasing) 
#Thrombocytosis (>1000x109/l) 
(persistent) 
#Thrombocytopenia not related to 
treatment (<1000x109/l ) 
Extramedullary blast 
accumulation 
Basophils in PB are ≥20% 
(basophilia) 
  
#Additional clonal cytogenetic 
abnormalities in Ph+ cells at dg that 
include major route abnormalities (, 
trisomy 8, trisomy 19, second Ph, 
isochromosome 17q,), abnormalities 
of 3q26.2 or complex karyotype. 
#Occurrence of any new clonal 
cytogenetic abnormality in Ph+ cells 
during the treatment 
*One item is enough for diagnosis, WBC, White blood cells. 
 
2. Epidemiology of CML 
CML comprises 15% of all cases of leukemia. The incidence of CML is estimated 
to be 1 to 1.5 per 100,000 persons per year, which is similar all over the world. The 
median age at onset of the disease is between 50 and 60 years. Age is considered to 
be an important parameter in CML, and it is included in the risk classification. The 
disease incidence increases slowly with age until the middle of the fifth decade; 
18 
 
after that, the risk progressively increases with age. Although CML is more likely 
to occur in adults, there is an 10% incidence among children and adolescents 1 to 
20 years old, comprising 3% of all cases of childhood leukemia. In regard to 
gender, the incidence of the disease is higher in males than in females.2,5,6 
 
3. Cellular and molecular pathology of the disease 
3.1. Molecular pathology 
CML occurs due to a chromosomal translocation within a normal stem cell 
chancing it to a leukemic stem cell. This pathological chromosome is called the Ph 
chromosome that has a characteristic short shape, and is formed by a head-to-tail 
fusion of the Abelson murine leukemia (ABL) gene on chromosome 9q34 with the 
breakpoint cluster region (BCR) gene located on chromosome 22q11 (t(9;22) 
(q34;q11.2). The Ph+ change within the hematopoietic stem cell results in a 
malignant transformation, although for the most part only the myeloid series are 
affected. The BCR-ABL1 fusion gene in the affected cells results in production of  
BCR-ABL1 tyrosine kinase (TK). Unlike the normal ABL1 TK that is located 
mainly in the nucleus of the cell,  BCR-ABL1 TK is located in the cytoplasm. 
BCR-ABL1 activates signal transduction pathways that cause continuous cell 
proliferation and inhibition of apoptosis. For example,  B-cell lymphoma 2 ( BCL-
2), the mitogen-activated protein kinases (MAPK), extracellular signal-regulated 
kinases (ERK), Janus kinases (JAK), signal transducer and activator of 
transcription (STAT) pathways, and MYC pathways are activated. In addition,  
BCR-ABL1 interactions cause also adhesive abnormalities, such as an activation of 
Crk-like protein (CRKL) and focal adhesion kinase (FAK) leading to decreased 
adherence to BM stromal cells. BCR-ABL1 also promotes gene damage and 
increases formation of injurious reactive oxygen species (ROS).1,2,7,8  
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3.2. Leukemic stem cells 
CML stem cells can undergo self-renewal and multilineage differentiation into 
various phenotypes involving all blood cell lineages.2,9,10 In CML, this primarily 
involves the myeloid cell lineage (erythrocytes, monocytes, granulocytes, and 
thrombocytes). In some patients, abnormal B-cells and T-cells (lymphocytes) have 
the Ph chromosome and BCR-ABL1.2 However, most of the abnormal B-cell and T-
cell progenitors undergo apoptosis.1,2,11,12 CML stem cells share general 
characteristics with other types of stem cells in that they have the potential to 
remain dormant. Most of the leukemic stem cells are in the G0 phase of the cell 
cycle, and they are resistant to CML treatment with TKIs.2,9,13 
The CML stem cells are CD34+CD38-, and are thought to play a primary role in 
CML progression and drug resistance.9,13–15 The leukemic progenitor cells are 
CD34+CD38+. In healthy adults, the majority of CD34+CD38+ cells express 
CD19 as a marker for normal progenitor B-cells. In contrast, in CML patients, 
CD19 is expressed only in a small percentage of the CD34+CD38+ cells, reflecting 
the myeloid nature of the disease.15  
The disease is usually diagnosed in the chronic phase (CP); if untreated, it 
progresses to the accelerated phase (AP) and the blast crisis (BC) phase within 4 
years. It has been shown that BC may also occur due to transformation of the 
progenitor CD34+CD38+ cells.1,5,9,16 Additional chromosomal changes and 
molecular secondary changes accumulate in CML cells, leading to the BC 
phenotype of enhanced proliferation and survival along with an arrest in 
differentiation.16 Transformation of the disease  to the BC phase is influenced by 
ROS and different cytokines and inflammation signals in a BM niche 
microenvironment.2,9,17 
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4. Symptoms 
CML is clinically asymptomatic in 50% of cases; in those cases, it is discovered 
accidentally through routine laboratory investigations. CML has previously been 
presented in a large percent of patients by an enlarged spleen, anemia, hemorrhage, 
and sweating. Bleeding tendency includes gingival, urinary tract, and 
gastrointestinal bleeding. Due to  an enlarged spleen, the patient can complain of 
abdominal discomfort, abdominal sense of fullness, increased intra-abdominal 
pressure, mechanical splenic pain, sense of heaviness, and possible spread of pain 
to the left shoulder. CML can also present by easy fatigability, loss of energy, 
headache, malaise, lethargy, and other symptoms of tiredness due to anemia. The 
thrombocytosis associated with leukocytosis in CML can lead to thromboembolic 
manifestations, including pulmonary embolism, myocardial infarction, 
cerebrovascular stroke, ophthalmological symptoms, and priapism. Dyspnea and 
fatigue can be presenting symptoms for the pulmonary embolic manifestations or 
cardiac problems. Arthralgia, bone pain, and a likelihood of developing gout due to 
high uric acid are musculoskeletal manifestations that can also occur with CML. 
With progression of the disease from CP to AP or BC, fever and infections become 
common. Lymphadenopathy and weight loss take place as well. Lymphadenopathy 
and fever are rare in CP.1,2,5 
 
5. CML diagnosis (dg) 
5.1. Clinical examination  
A palpable spleen is the most frequent finding on clinical examination. Spleen size 
can vary from only detectable by imaging to just palpable,  but in some cases, the 
spleen passes the umbilicus and reaches the right iliac fossa. Spleen enlargement at 
21 
 
dg is considered as a negative factor in estimating the risk stage of CML (Table 
4).1,4,5 
5.2. Laboratory work  
CML is detected and assessed mainly through different diagnostic levels: cellular, 
cytogenetic, and molecular levels. Cell counts and cellular morphology are 
assessed by cell counting, blood film picture evaluation, and BM examination. 
Cytogenetics is assessed through chromosomal examination to detect the Ph 
chromosome, usually by karyotyping or fluorescence in situ hybridization (FISH) 
technique. The molecular level assessment is done through detection of BCR-ABL1  
gene transcript copies via real-time quantitative polymerase chain reaction (RQ-
PCR).1,4 
5.2.1. Cellular counts and morphology 
At dg, the white blood cell (WBC) count usually ranges between 20 x109/l and 200 
x109/l (normal is 4 x109/l to 10 x109/l) in CP CML. However, the WBC count may 
be as high to 800 x 109/l.1,2 An increase in the WBC count is due to the increased 
proliferation of the myeloid cell lineage. This results in immature granulocyte 
lineage cells appearing in the blood film, where both mature and immature cells 
(promyelocytes, myelocytes, and myeloblasts) can be observed. In general, PB 
granulocytes have a normal morphology, and the blast proportion is usually low. 
The basophil count is an important parameter in CML staging. In CP CML, both 
the absolute and relative basophil counts increase, but the relative basophilic counts 
do not exceed 15%. In AP CML, the PB basophil counts reach or exceed 20%. 
Typically, although the absolute eosinophil counts increase, the relative counts do 
not. The platelet counts are elevated in 50% of all patients, and platelet counts are 
also used in CML staging.1,2,4 There is also an increase in the absolute lymphocyte 
count due to an increase in the number of T-helper and T-suppressor cells; however 
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the  B-cell count does not increase.  The relative lymphocyte counts decrease 
because the CML-induced malignant proliferation in granulocytes is much higher 
than the increase in the lymphoid lineage, which only correlated to a reactive 
change in the disease.1,2,18 
In the diagnostic BM, taken either as an aspirate or a biopsy, hypercellularity is due 
to increased myeloid activity, with hematopoietic cells occupying the majority of 
the BM tissue. The number of adipose cells is markedly reduced. Granulocytes are 
predominant, with a marked increase in the granulocyte:erythrocyte ratio. While 
the normal ratio ranges from 2:1 to 4:1, in CML the ratio can be as high as 30:1. 
With TKI therapy, the blood picture is usually normalized, which is known as a 
complete hematologic response (CHR).1,2,4 
5.2.2. Cytogenetics  
Cytogenetic analysis is very important at dg as well as during follow-up of CML. 
At dg, the test is done for CML detection; during follow-up, to assess the response 
to treatment. Cytogenetic responses (CyR) are defined in Table 2. Cytogenetic 
assessment for Ph is performed by either conventional karyotyping (standard G-
banding method) or FISH technique. In conventional karyotyping at least 20 BM 
metaphases are evaluated for Ph positivity. False positivity is rare, but false 
negativity can occur. 
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Table 2. Cytogenetic response definitions. 
Response Ph+ chromosome in cells 
Lack of cytogenetic response (no CyR) >95% of cells still have Ph+ chromosomes after treatment 
Minor cytogenetic response (mCyR)  >35% of cells still have Ph+ 
Major cytogenetic response (MCyR)  1–35% of cells still have Ph+  
Partial cytogenetic response (PCyR)  <35% of cells still have Ph+, but not 0 cells 
Complete cytogenetic response 
(CCyR)  No detected cells have Ph+  
 
FISH technique is the newer way of assessing Ph+ by cytogenetics. A BM sample 
is not necessarily needed, as the measurement can also be done by a  PB sample.  
Approximately 200–1000 cells in interphase or metaphase are analyzed for Ph+ 
chromosome by FISH. False negativity can occur.2,4,15,19–22 
5.2.3. Molecular analysis 
Molecular analysis is currently the most recent and most important test for follow-
up. It is done by quantifying BCR-ABL1 gene transcripts in the blood through RQ-
PCR.  The number of BCR-ABL1 transcripts is compared to the number of 
transcripts of a reference gene, which can be either the  ABL or the β-glucuronidase 
(GUS) gene. The BCR-ABL1/control gene ratio is reported in the standardized 
international scale (IS).23 The sample for PCR analysis can be either from PB or 
BM. PB samples are the most widely used, because these are easily accessible and 
practical. The PCR test is usually performed at dg, then in follow-ups at 3 months, 
6 months, 12 months, and later. The different molecular responses are shown in 
Table 3.4,19,23,24 
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Table 3. The different molecular responses.4,19,23,24 
Response BCR-ABL1 expression  
MMR BCR-ABL1 levels <0.1% 
MR4.0 BCR-ABL1 levels <0.01% 
MR4.5 BCR-ABL1 levels <0.0032% 
Molecularly undetectable 
leukemia 
No BCR-ABL1 transcript is 
detectable with PCR 
(the best response) 
  
5.3. Risk classification and staging at dg 
Different multivariable analysis scoring systems are used in risk staging of CML at 
diagnosis. These scoring systems include:  Sokal, Euro, and the European 
Treatment and Outcome Study (EUTOS). Different variables are used in these 
scoring systems, including spleen size, age, and cell counts. The Sokal scoring 
system, which was introduced in 1984, was the first to evaluate  risk factors at 
diagnosis. It uses the following formula:  Exp 0.0116 x (age in years – 43.4) + 
0.0345 x (spleen size in centimeters – 7.51) + 0.188 x ([platelets in 109/l divided 
with 700]2 – 0.563) + (0.0887 x [blast cells in percentage] – 2.10). In 1998, the 
Euro scoring system (known also as the Hasford score) was introduced. The Euro 
score uses the following formula: 0.6666 if the patient’s age is equal to or greater 
than 50 years + (spleen size in centimeters x 0.0420) + (0.0584 x percentage of 
blasts) + (percentage of eosinophils x 0.0413) + 0.20399 if the percentage of 
basophils is greater than 3% + 1.0956 if the platelet count is greater than 1500 x 
109/l x 100. The Sokal and Euro scores classify patients into high-, intermediate-, 
and low-risk groups. The EUTOS scoring system was introduced in 2011 to predict 
the patients that will reach cytogenetic remission at 18 months of treatment by 
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classifying them into low risk (reaches remission) and high risk (will not reach 
remission) groups. The EUTOS score uses the following equation: Exp (−2.1007 + 
0.0700 × basophils + 0.0402 × size of spleen)/(1 + exp [−2.1007 + 0.0700 + 
basophils + 0.0402 × size of spleen]) (Table 4).4,25–27  These scoring systems have a 
high efficiency in predicting the outcome of TKI treatment and in estimating 
progression-free survival with the use of TKIs.28,29 They are also used to compare 
the effects of different TKIs.30 
Table 4. Sokal, EURO, and EUTO CML grading systems: factors for calculations 
and risk grading. 
  Sokal EURO EUTOS 
Factors used in 
calculation 
Age, spleen 
size, platelet 
count, and 
blasts 
Age, spleen size, 
platelet count, 
blasts, basophils, 
and eosinophils 
Spleen size 
and basophils 
Risk grading       
Low risk <0.8 <780 <87 
Intermediate 
risk 0.8–1.2 781–1480   
High risk >1.2 >1480 >87 
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6. CML treatment 
As previously discussed, CML is caused by the BCR-ABL1 mutation in the Ph 
chromosome, which leads to the formation of a pathologic BCR-ABL1 protein 
kinase that causes continuous and uninhibited proliferation of myeloid cells. TKIs 
are therapies targeted toward the TK protein, and they are highly selective in 
binding with the BCR-ABL protein kinase. They target the adenosintriphosphate 
(ATP) site of the TK substrate in the TK receptor, bind to it, and block it. This 
inhibits cell replication and proliferation of the BCR-ABL1 bearing malignant CML 
cells (Figure 1). TKIs were first introduced in clinical practice in year 1996 by 
scientists. The treatment tremendously decreased tumor load and caused 
cytogenetic and molecular responses in CML patients.1 
 
Figure 1. TKIs competitively bind to the ATP binding site of the kinase and 
block it. 
 
6.1. Imatinib 
Imatinib was the first TKI to be introduced for CML. It is used as a first-line 
therapy for newly diagnosed CML patients. The typical imatinib dose is 400 
mg/day for CP CML, and it can be elevated from 600 up to 800 mg/day in cases of 
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disease progression and/or AP CML and BC CML. Side effects of imatinib include 
gastrointestinal disturbances, such as nausea, vomiting, dyspepsia and diarrhea. 
Edema that can be preorbital, facial, or tibial is another adverse effect of imatinib. 
Imatinib can also cause musculoskeletal side effects, such as cramps and arthralgia, 
or hematological side effects, such as neutropenia, thrombocytopenia, and anemia. 
1,2,4 
6.2. Dasatinib  
As all patients do not satisfactorily respond to imatinib treatment, novel second-
generation TKIs have been developed: dasatinib, nilotinib, and bosutinib. Dasatinib 
was the first of the second-generation TKIs to be introduced. The TK inhibition 
spectrum of dasatinib is wider than that of imatinib, as it targets many other TKs in 
addition to the BCR-ABL TK. It is used both as a first and second line therapy in 
imatinib resistant or intolerant patients with CP, AP, or BC. The dasatinib dose is 
100 mg/day in the CP and elevated to 140 mg/day in cases of AP and BC.1,2,4,31,32 
Inflammatory adverse effects, such as edema, pleural effusion, colitis, and fever are 
characteristic for dasatinib, and they are associated with  increased lymphocytosis. 
Pleural effusion can occur in up to half of patients treated with dasatinib, the risk 
factors including increasing age and/or cardiopulmonary morbidities.2,33,34 Pleural 
effusion can present as an early or late complication. Treatment of pleural effusion 
is symptomatic and includes drug interruption, corticosteroids, diuretics and 
tapping of fluid. Change to another TKI is needed if the problem persists. 
However, sometimes pleural effusion continues also with another TKI.1,31,35–37 
Other adverse effects include rash and hypophosphatemia.2,4,32  
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6.3. Nilotinib 
Nilotinib is another second-generation TKI proven to be effective for resistant and 
intolerant CML patients. In addition to being active against BCR-ABL1, it is also 
active against  other mutated protein kinases, such as platelet derived growth factor 
receptors (PDGFR). It is used either as a first-line therapy in CP CML or as a 
second-line therapy in case of resistance or intolerance to at least one TKI. It is 
mainly used as a second-line treatment for CP CML or AP CML; currently, there 
are some recommendations for its use in BC CML as well. Data from ENESTnd 
studies 38,39 also favors its use in first-line, due to its greater effectiveness compared 
to imatinib in preventing AP CML and BC CML. The drug is taken on empty 
stomach with a dose of 300 mg twice a day (BID). Food has to be avoided for 2 
hours before and 2 hours after the dose. In the case of AP (or BC), the dose is rised 
to 400 mg/BID. Adverse effects include gastrointestinal upset, rash, elevated liver 
function tests, hyperglycemia, and hypophosphatemia. Nilotinib treatment has also 
been associated with an increased risk of peripheral arterial occlusive disease.1,2,4 
6.4. Bosutinib 
Bosutinib is a new second-generation TKI that has been approved for cases that are 
resistant or intolerant to imatinib, nilotinib, and dasatinib. It is used for all the three 
phases of CML. The dose is 500 mg/day taken with food. Side effects are reported 
to be gastrointestinal issues, rash, and elevated liver function tests.1,2,4 
 
7. TKIs and treatment responses  
For first-line TKIs, treatment responses for different time points according to the 
European leukemia network (ELN) recommendation4 are summarized in Table 5.  
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Table 5. Treatment responses for first-line TKI therapy according to the ELN 
recommendation.4 
  Optimal Warning Failure 
Baseline NA 
High risk  
or clonal cytogenetic 
abnormalities in Ph+ 
cells  
NA 
3 mo 
BCR-ABL1 levels 
<10% 
and/or CCyR or 
PCyR 
BCR-ABL1 levels 
>10% 
and/or mCyR 
No CHR 
and/or no CyR 
6 mo BCR-ABL1 levels < 1% and/or CCyR 
BCR-ABL1 levels 1–
10% and/or PCyR 
BCR-ABL1 levels 
>10%  
and/or no PCyR 
12 mo 
MMR or BCR-
ABL1 levels equal 
0.1 
BCR-ABL1 levels 
>0.1–1% 
BCR-ABL1 level > 
1% 
and/or no CCyR 
Any time 
after 12 mo 
MMR or BCR-
ABL1 levels equal 
to 0.1 
Clonal cytogenetic 
abnormalities in Ph- 
cells, with 
abnormalities in 
chromosome 7 
Loss of molecular 
undetectability  
Loss of CCyR 
Loss of MMR in 2 
consecutive tests 
Clonal cytogenetic 
abnormalities in Ph+ 
cells  
 
7.1. Imatinib as the first generation TKI  
Responses with imatinib are very satisfactory. The 5-year progression-free survival  
rate (no progression to AP or BC or no loss of achieved MR) according to the IRIS 
study 28  is 97% for patients who reached CCyR at 12 months, 93% for patients 
who achieved PCyR, and 81% for patients who achieved less than PCyR. However, 
40–50% of patients may discontinue the treatment due to intolerance or resistance.  
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Among patients diagnosed in CP, the 12-month MMR for imatinib ranges from 22 
to 33%, and CCyR at 1 and 2 years is 65–72% and 77–82%, respectively, 
1,2,4,30,32,38–41 (Table 6). Imatinib can safely be discontinued after 2 years of  non- 
detectable BCR-ABL1 measures in PCR. More than 40% of patients that 
discontinued imatinib after 12 and 24 months of achieving non-detectable BCR-
ABL1 did not relapse. 42–44  
7.2. Second generation TKIs 
In dasatinib treated CP CML patients, CCyR and MCyR are achieved in around 
80% and MMR in around 45% of patients (Table 6).  
With nilotinib treatment MRs and early MRs according to ELN recommendations 
(BCR-ABL1 levels <10% at 3 months) were achieved more often than with imatinib 
treatment. 
According to ENESTnd, CCyR is achieved with nilotinib treatment in 80% and 
87% of patients at 1 and 2 years, respectively. Between 50% and 55% of patients 
on nilotinib treatment reach MMR by 12 months, according to ENESTnd and other 
reported studies (Table 6).1,2,4,30,32,38–40   
When either nilotinib or dasatinib are given as first-line therapy, they can safely be 
stopped after 24 to 48 months of deep molecular responses.44–46 Administration of 
dasatinib can be discontinued  1 year after achieving a deep molecular response, 
with a non-relapse possibility of nearly 50%.45 Conversely, when dasatinib and 
nilotinib are given as second-line treatment for resistant cases or cases with a 
suboptimal response, the post-treatment results are not satisfactory. 46 
Patients who take bosutinib after failure with one of the other TKIs have a good 
chance (50%) of achieving CCyR. However, the chances of achieving CCyR 
decrease to around 20–30% when bosutinib is used as a third-line therapy. 1,2,4 
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Table 6. Responses for CP CML cases with different first-line 
treatments.1,2,4,30,32,38–40 
  1-year MMR 1-year CCyR  2-year CCyR 
Imatinib 22–33% 65–72% 77–82% 
Dasatinib ~46% 83% 85% 
Nilotinib 50–55% 80% 87% 
 
Although TKIs are potent and can be successfully used to treat CML, it is not clear 
why some patients fail to achieve the desired response. In clinical practice, early 
prediction of treatment outcome is very important in guiding the potential TKI dose 
and/or in making treatment changes. To date, according to studies and 
recommendations, the earliest response evaluation is being done 3-months after 
treatment; cases with BCR-ABL levels less than 10% at 3 months are considered to 
be optimally responding, and cases with BCR-ABL1 levels greater than 10% at that 
time point are considered to be non-optimal responders.4,47 
 
8. Immunological effects of TKI therapy  
Several studies have reported that, despite of primarily working on TK 
oncokinases, TKI treatment can also have secondary effects on the immune system 
and lymphocyte behavior. Such secondary effects could also be taken into 
consideration when deciding about the treatment as well as assessing the patient’s 
prognostic status.21,37,48  
Recent studies have shown that dasatinib treatment causes lymphocytosis and LGL 
proliferation in some CML patients. Dasatinib also causes rapid mobilization of 
cytotoxic lymphocytes, which may be related to the inflammatory edematous 
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effects of the drug. Dasatinib-induced lymphocytosis can also be considered as an 
useful anti-leukemic immune response that gives an extra advantage to the drug. A 
similar lymphocytic expansion has not been observed during imatinib or nilotinib 
treatment.31,35–37 However, imatinib is also known to affect lymphocytes. In 2007, 
it was shown that BM lymphocytosis occurred during imatinib treatment and was 
associated with optimal therapy response. BM lymphocytosis after 3 months of 
imatinib treatment predicted CCyR and MMR at 12 and 18 months of therapy.21  
In vitro assays have shown that TKIs have immunosuppressive effects, by 
suppressing T cell function (in vitro media??) as well as CD4+ and CD8+ T cell 
proliferation.49–53 TKIs have also been reported to have immunosuppressive effects 
on B cells by suppressing B cell proliferation and function (such as reduction in 
memory B cells and IgM production).54–56 These findings raise a question whether 
TKIs predispose patients to infections. Some studies have shown that TKI 
administration is associated with infection complications, such as hepatitis B virus 
(HBV), cytomegalovirus (CMV), and herpes simplex virus (HSV) activation.52 In 
addition to HBV reactivation reported for imatinib, upper respiratory tract 
infections (URTIs) have also been observed.28,57 Reports on nilotinib treatment 
associated infections are scarce, and the reported infection rates are low.58 During 
dasatinib treatment, infections were reported to occur in 11% of patients whereas 
the number was only 7% in imatinib treated patients.59 Occurrence of URTIs are 
reported in conjunction with bosutinib treatment; however, the data is still 
inadequate.52,60 In large clinical trials, the use of TKIs has not been related to an 
increase of opportunistic infections. In addition, the development of severe 
infectious complications or high-grade infections is reported to be rare. The 
majority of infections reported have been controllable with no major undesirable 
consequences.49–53  
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9. In conclusion 
The use of TKIs has dramatically affected the prognosis of CML patients. 
Currently, these patients live quite normal lives, and the life expectancy is close to 
that of healthy individuals. However, a small fraction of patients still does not 
respond satisfactorily to the TKI treatment. Therefore, early treatment response 
predictions are needed. In addition, as the treatment with TKIs is lifelong in many 
cases, it is important to analyze the off-target effects that the treatment may cause. 
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AIM OF THE STUDY 
The aim of this PhD project was to find early predictors for treatment response and 
to evaluate the immunological effects of TKI therapy. Specific aims: 
Study I: To identify whether early decline of BCR-ABL1 levels could predict later 
treatment response. 
Study II: To determine whether all the studied TKIs induce BM lymphocytosis and, 
if so, how this affects treatment response. 
Study III: To study the effect of first-line TKI treatment on humoral immunity and 
associated infectious complications. 
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PATIENTS AND METHODS  
10. Patients 
All patients in the studies were newly diagnosed with CP CML and obtained TKIs 
as a first-line treatment. The patients were recruited from Nordic countries, namely, 
Finland, Sweden, and Norway. The centers involved in the studies from these three 
countries were: Helsinki University Central Hospital (Helsinki, Finland), Skåne 
University Hospital (Lund, Sweden), Umeå University Hospital (Umeå, Sweden), 
Uppsala University Hospital (Uppsala, Sweden), Karolinska University Hospital 
(Stockholm, Sweden), St. Olav’s Hospital (Trondheim, Norway), and Haukeland 
University Hospital (Bergen, Norway). These patients were enrolled from clinical 
trials of the following study cohorts: NordCML006 (NCT00852566), ENEST1st 
(NCT00519090), ENESTnd (NCT00471497), and Bfore (NCT02130557). Enrolled 
patients from NordCML06, ENEST1st, and ENESTnd had imatinib, dasatinib, or 
nilotinib as a first-line TKI (studies I, II, and III), while Bfore patients had 
bosutinib as a first line (study III). More details are shown in Table 7. 
 
 
 
 
 
 
 
 
36 
 
Table 7. Enrollment of patients in our research. 
 
Study I Study II Study III 
Patients are enrolled 
from the following 
clinical trials 
NordCML06 
and ENESTnd 
NordCML006 
and ENESTnd 
+ 45 patients 
outside the 
clinical trials 
NordCML06, 
ENEST1st, 
ENESTnd, and 
Bfore 
Total enrolled patients 52 105 56 
Number of patients on 
imatinib 26 71 20 
Number of patients on 
dasatinib 21 25 16 
Number of patients on 
nilotinib 5 9 8 
Number of patients on 
bosutinib   
12 (PB samples  
only) 
Healthy controls 
 
14 19 
 
11. Ethical considerations 
Written informed consent was obtained from study patients prior to sample 
collection. The ethics committees from the participating study centers approved the 
study. We followed the declaration of Helsinki. 
 
12. Clinical history, assessment, and disease-related laboratory analysis  
At dg, patients were subjected to a full clinical history, a clinical assessment, and 
an examination, including an evaluation of spleen size for studies I and II. The risk 
status for CML at dg was scored using the Sokal and EURO scoring systems.4,25,27 
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A complete laboratory assessment for the patients included a full blood picture 
with differential WBC counts, BM morphology analysis, BM karyotyping, and PB 
RQ-PCR for BCR-ABL1 molecular analysis. Time points for the laboratory 
assessment were as follows:  
Study I: At dg, then in follow-ups at 1, 3, 6, 12, 18, 24, and 36 months after 
beginning of the therapy. 
Study II: At dg, then in follow-ups at 3, 6, 12, and 18 months after 
beginning of the therapy. 
Study III: At dg, then in follow-ups at 1, 3, 6, 12, 18, and 24 after beginning 
of the therapy. 
12.1. Morphological assessment of bone marrow (BM) samples 
Morphological assessment of BM samples was performed in all studies, but it was 
of pivotal importance in study II.  
BM differential counts, including proportion of lymphocytes, basophils, 
promyelocytes, and blasts, were obtained from MGG-stained BM aspirate slides. 
For every sample, two slides were used, and three different fields per slide were 
counted at each time point (total of 500 cells were counted per slide). 
12.2. Karyotyping and FISH for detection of Ph chromosome 
Karyotyping was done using the standard G-banding analysis technique. We 
examined 20 metaphases per slide.15,61  
In study I, FISH analysis was performed on flow–cytometry-separated BM cell 
populations, namely Ph+ CD34+CD38- cells, and Ph+ CD34+CD38+ cells. A 
dual-fusion dual-color BCR-ABL1 probe was used in the analysis (Vysis, Abbot, 
Downers Grove, IL, USA).  
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In study II, we performed FISH for some follow-up samples in addition to the 
normal karyotyping. 
12.3. Molecular analysis 
RQ-PCR was used to detect BCR-ABL1 transcript levels in cells of PB samples by 
using TaqMan® chemistry. Real time reaction conditions and RQ-PCR assays 
were done in accordance with the protocol of the Europe Against Cancer (EAC) 
Program24, using GUS or ABL as reference genes. BCR-ABL1 values were reported 
in the IS as percentage values. 
 
13. Mononuclear cells and plasma separation 
Mononuclear cells were separated from PB and BM samples with Ficoll gradient 
according to the instructions of the manufacturer (GE Healthcare) and stored as 
cryopreserved cells in fetal bovine serum with 10% dimethylsulfoxide (DMSO) in 
aliquots in liquid nitrogen. Plasma was separated by centrifugation and stored at -
70oC.  
13.1. Ig measurement in the plasma samples 
We used the frozen and stored plasma samples to measure plasma Ig levels, 
specifically IgM, IgA, and IgG. Samples were analyzed using the 
immunoturbidometric method62 in the Helsinki University Central Hospital 
laboratory (HUSLAB). The Finnish national reference values were used in the 
study: IgM 0.36–2.84 g/l, IgA 0.52–4.84 g/l, and IgG 6.8–15 g/l. 
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14. Flow cytometry 
14.1 Flow cytometry analysis 
The samples in Study II and Study III were analyzed by multicolor flow cytometry 
using the FACSAriaI/IITM flow cytometry device (BD Biosciences, San Jose, CA, 
USA) and FACSDIVA software (Becton Dickinson). In both studies, mononuclear 
cells from the PB and BM samples were analyzed at all the studied time points (at 
diagnosis and during the therapy follow-ups). 
Study II:  The cells were analyzed by flow cytometry using the following marker 
panels. Panel 1 was used for T-cell phenotyping (CD3, CD4, CD8, CD45RA, and 
CD45RO), panel 2 was used to assess the T-cell surface receptors (CD3, 
CD8TCRαβ, and TCRγδ), panel 3 was used to evaluate the percentages of different 
lymphocyte subsets (CD45, CD16+56, CD57, and CD19), panel 4 was used to 
evaluate  the T-cell activation status (CD3, CD4, CD8, CD62L, HLA-DR, and 
cyKi-67), and panel 5 was used to measure the proportion of regulatory T-cells 
(Tregs) (CD3, CD4, CD25, and Foxp3).  
Study III: The PB and BM samples from all time points were analyzed from the 
patients treated with imatinib, dasatinib, and nilotinib. For the patients treated with 
bosutinib, only the PB samples at diagnosis and at the 3- and 12-month follow-ups 
were analyzed. First, to measure the number of B-cells in the PB and BM samples 
the following markers were used: CD45, CD3, and CD19. Next, to investigate the 
maturational stages of BM in the B-cells, extra gatings for the BM samples where 
done, as follows: CD19+CD45high mature, CD19+CD45intermediate maturing, and 
CD19+CD45low immature B-cells.63,64 Finally, to further identify the B-cell 
subpopulations, the following markers were used: CD3, CD19, CD38, CD27, IgM, 
and IgD. Consequently, the gated subpopulations included: B-cells (CD3-CD19+), 
mature naïve B-cells (CD19+CD27-), mature memory B-cells (CD19+CD27+), 
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class-switched memory B-cells (CD19+CD27+IgM-IgD-), marginal zone-like 
memory B-cells (CD19+CD27+IgM+IgDlow), transitional B-cells 
(CD19+CD38+IgM+), and plasmablasts (CD19+CD38highIgM-). 
Table 8 shows the panels and antibodies that were used. 
Table 8. Antibodies and panels used in flow cytometry analysis. 
  Study II* Study III 
Panel 1 
CD3, CD4, CD8, CD45RA, 
CD45RO  
 
CD45, CD3 and CD19 
 
Panel 2 CD3, CD8TCRαβ, TCRγδ  
 CD3, CD19, CD38, 
CD27, IgM, IgD  
 
Panel 3 
CD45, CD3, CD16+56, CD57, 
CD19 
 
  
Panel 4 
CD3, CD4, CD8, CD62L, HLA-
DR, cyKi-67 
 
  
Panel 5 CD3, CD4, CD25, Foxp3  
  
*All panels in study II were performed on BM and PB samples.  
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14.2. Flow cytometry sorting 
In study I, CD34 positive cells were separated from the liquid nitrogen-stored 
mononuclear cells using paramagnetic beads (Miltenyi Biotech, Bergisch 
Gladbach, Germany). CD34 positive cells were stained with CD34 and CD38 
antibodies (BD Biosciences, San Jose, CA, USA) and sorted via the FACS Aria 
flow cytometry device into cells with low CD38 expression (Ph+CD34+CD38- 
cells) and cells with a high CD38 expression (Ph+CD34+CD38+).  
  
15. Statistical analysis 
GraphPad prism 6.0 (GraphPad Software Inc.) and SPSS 22 (SPSS Inc.) were used 
for statistical analysis. Mann Whitney tests, t-tests, one- or two-way analyses of 
variance (ANOVAs), and chi-squared tests were performed when appropriate. P-
values were considered significant at <0.05. 
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RESULTS 
16. Patient division according to fold change (FC) in BCR-ABL1 levels after 1 
month (I) 
In study I, the 52 enrolled patients were divided into two main groups, namely poor 
responders and responders. The division was based on changes in BCR-ABL1 
transcript levels between the values recorded at dg (just before the start of TKI 
therapy) and the values after 1 month of TKI therapy. The patients with no 
decrease in BCR-ABL1 levels were called poor responders. These poor responders 
had a FC in BCR-ABL1 levels higher than 1 (i.e., the value of BCR-ABL1 at 1 
month was higher than at dg, FC>1). The patients with a decrease in BCR-ABL1 
levels were called responders. These responders had a FC in BCR-ABL1 levels 
lower than 1 (i.e., the value of BCR-ABL1 levels at 1 month was lower than at dg, 
FC<1). The median value of responders was 0.31. We further divided the 
responders into two groups according to the FC values: good responders had FC 
<0.31 and intermediate responders had FC ≥0.31 and ≤1 (0.31≤FC≤1). The 
division process is shown in Figure 2. 
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Figure 2. Evaluation and classification of patients according to BCR-ABL1 
response after 1 month of TKI. Patients were first divided into two groups based 
on the difference between BCR-ABL1 levels at dg and 1 month. Patients with a FC 
higher than 1 were classified as poor responders, and patients with FC<1 were 
classified as responders. Responders were further divided into good responders 
(FC<0.31) and intermediate responders (0.31≤FC≤1). 
 
17. One fifth of patients responded poorly after 1 month of treatment with 
TKI (II) 
When measuring the FC for the 52 patients after 1 month of first-line TKI therapy, 
we found that one fifth of the patients (n=11, 21% of the total) had FC>1, which 
means that their BCR-ABL1 levels did not decline. On the contrary, those patients 
had markedly increased BCR-ABL1 levels when compared to the dg values. We 
investigated the factors causing a lack of decline in BCR-ABL1 levels for this group 
of patients. We checked, most importantly, that all patients were compliant with 
TKI therapy (that they took the prescribed doses continuously with no skipping of 
doses). In addition, we checked their data to ensure that there were no reports of 
discontinuation of therapy for any reason. The rest of the patients showed a decline 
in BCR-ABL1 values, and we described them accordingly as responders (n=41; 
Figure 2). 
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17.1. Factors associated with poor response 
17.1.1. The BCR-ABL1 levels of poor responders were lower than responders at dg 
BCR-ABL1 transcript numbers in PB are expressed as their ratio to the reference 
gene used (BCR-ABL1/control gene ratio) and reported in the standardized IS as 
percentages. 
Surprisingly, the BCR-ABL1 levels for poor responders at dg were significantly 
lower than those of the responders. The median BCR-ABL1 level for poor 
responders was 30.5% (range 10.9–47.2), while it was 47.8% (range 12.9–156.5) 
for responders (p<0.01; Figure 3).  
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Figure 3. Poor responders have significantly lower BCR-ABL1 values than 
responders (p<0.01) at dg. 
  
 
17.1.2. Poor responders had a higher leukemia stem cell burden 
The Ph+CD34+ CD38- leukemia stem cells at dg were significantly higher in the 
poor responders group than in the responders group (medians were 91.3% [range 
73.4–100%] and 75.3% [range 0.6–98.5%] for poor responders and responders, 
respectively; p<0.05; Figure 4). The proportion of Ph+CD34+CD38+ progenitor 
cells between poor responders (median 99%) and responders (94.9%) did not show 
a significant difference. 
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Figure 4. Poor responders have significantly higher Ph+CD34+CD38- stem 
cells than responders (p<0.05) at dg.  
 
17.1.3. Poor responders had larger spleens 
Splenomegaly was more frequent among poor responders when compared to 
responders. More than half of the poor responders had enlarged spleens (6 cases 
out of 11; 54.5%). For the responders, only six cases out of 41 had splenomegaly 
(14%) (pchi square<0.01; Figure 5). Spleen size was also larger in poor 
responders; the median spleen size for poor responders was 5 cm below the costal 
margin, while it was zero for the responders (t-test p<0.05) 
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Figure 5. Poor responders had significantly enlarged spleens at dg (pchi square 
<0.01).  
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17.1.4. Poor responders had lower hemoglobin values than responders 
At dg, the median hemoglobin levels among the poor responders was below the 
normal range, and it was also significantly lower than in the responder group 
(median hemoglobin levels were 105g/l[range 88–122g/l] and 128g/l [range 82–
154g/l] for poor responders and responders, respectively; p<0.001; Figure 6). 
No differences in other parameters (such as age, sex, Sokal and EURO scores, 
WBCs, lymphocytes and blasts) were observed (table 9). 
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Table 9. Age, sex, Sokal and EURO scores, WBCs, lymphocytes and blasts did not 
show differences between responders and poor-responders. 
  Responders Poor-responders 
Patients numbers 41 11 
Sex 
Males 20 6 
Females 21 5 
Age* 57 (35-78) 53 (29-64) 
Sokal risk 
group  
High  8 2 
Intermediate 14 5 
Low 19 4 
Sokal score* 0.8 (0.56-13.22) 0.89 (0.57-4.2) 
EURO risk 
group 
High  3 1 
Intermediate 22 6 
Low 16 4 
EURO score* 873 (100-2066) 866 (403-1839) 
At diagnosis 
BM blasts in percent* 2 (0-9) 2 (1-4) 
BM lymphocytes in 
percent* 3.5 (1.10) 2 (0-13) 
BM basophils in percent* 2 (0-10) 2.5 (0-5) 
PB WBC [in 109/L]* 44.7 (2.4- 288.4) 46.6 (5.6- 169.5) 
PB relative lymphocyte 
count in percent* 9 (2-35) 6 (1-16) 
PB absolute lymphocyte 
count [in 109/L]*  3.4 (0-11.7) 2.7 (0.5-15.5) 
At 3 months 
post TKI  
BM blasts in percent* 1 (0-3) 1.5 (1-5) 
BM lymphocytes in 
percent* 27 (7-40) 19 (14-38) 
BM basophils in percent* 0 (0-2) 1 (0-1) 
PB WBC [in 109/L]* 5 (2-8.8) 4.6 (2.2- 7.6) 
PB relative lymphocyte 
count in percent* 36 (3-70) 30 (14-48) 
PB absolute lymphocyte 
count [in 109/L]*  1.7 (0.1-4.4) 1 (0.6-2.4) 
*Median (minimum-maximum) 
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Figure 6. Poor responders had lower hemoglobin levels (p<0.001) at dg. 
 
17.2 Poor responders showed slower eradication of Ph+ cells in stem and 
progenitor cell compartments 
17.2.1. BCR-ABL1 levels decreased more slowly in poor responders 
BCR-ABL1 values showed a significant and obvious increase in poor responders at 
1 month after start of TKI treatment, as the median value increased from 30.5% at 
dg to 40.2% at 1 month (p=0.04). By contrast, BCR-ABL1 values dramatically 
decreased in the responders group; median values dropped from 47.8% at dg to 
13.9% after 1 month (p<0.0001). When comparing both poor responders and 
responders at 1 month, the poor responders’ BCR-ABL1 levels were significantly 
higher (median values were 40.2% [range 11–98.7] and 13.9% [range 0.9–106.6] 
for poor responders and responders, respectively; p<0.01; Figure 7). 
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Figure 7. At 1 month, poor responders have higher BCR-ABL1 levels (median 
40.2%, range 11–98.7) compared to responders (median 13.9%, range 0.9–
106.6; p<0.01). 
 
17.2.2. Poor responders eradicate Ph+ cells from the stem and progenitor cell 
compartments more slowly 
Following the changes in BCR-ABL1 levels, in the responders group 
Ph+CD34+CD38- cells drastically decreased at 1 month after starting therapy; the 
median value dropped significantly, from 75.3% at dg to 11.1% at 1 month 
(p<0.0001). By contrast, the decrease in the poor responders was mild; median 
values decreased from 91.3% at dg to 56.2% at 1 month (p<0.05). When comparing 
poor responders and responders at 1 month and 3 months, the poor responders' 
Ph+CD34+CD38- cells were significantly higher (at 1 month, median values were 
56.2% [range 1.1–97%] and 11.1% [range 0–9.98%] for poor responders and 
responders, respectively [p=0.11]; at 3 months, the median values were 2.8% 
[range 0–34.86%] and 0.2% [range 0–7.8%] for poor responders and responders, 
respectively; p<0.01; Figure 8 A). 
Similar to the Ph+CD34+CD38- cells, also Ph+CD34+CD38+ cells in the 
responders group dramatically decreased at 1 month after start of the therapy; the 
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median value dropped significantly from 94.7% at dg to 31.9% at 1 month 
(p<0.0001). By contrast, in poor responders the Ph+CD34+CD38+ cells were 
notably high at the 1-month time point, as the median values decreased only from 
99% at dg to 86.5% at 1 month (p<0.05). When comparing poor responders and 
responders at 1 month, the poor responders' Ph+CD34+CD38+ cells were 
significantly higher (at 1 month, the median values were 86.5% [range 34.2–94.8] 
and 31.9% [0.9–98.6] for poor responders and responders, respectively; p<0.01; 
Figure 8 B). 
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Figure 8. At 1 month, poor responders have slower eradication of Ph+CD34+ 
cells. A) Ph+CD34+CD38- cells significantly dropped in responders but decreased 
more slowly in poor responders. The difference between the drop for poor 
responders and responders was significant at 3 months (p<0.01). B) 
Ph+CD34+CD38+ cells significantly dropped in responders but decreased very 
slowly in poor responders. The difference between the drop for poor responders 
and responders was also significant at 1 month (p<0.01) 
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17.3. Poor responders had an inferior long-term treatment response  
17.3.1. Poor responders had 3-month BCR-ABL1 levels greater than 10% 
At 3 month time point all good responders (17 patients) had BCR-ABL1 levels less 
than 10%. In the group of intermediate responders 16 patients out of 21 had levels 
less than 10%, whereas in the group of poor responders only 4 patients out of 11 
had levels less than 10%.(Figure 9). 
Figure 9. 36% of poor responders did not achieve BCR-ABL1 levels <10% at 3 
months, while all responders did.  
 
17.3.2. Poor responders had inferior MMR rates at 12 and 18 months when 
compared to responders  
In follow-ups at the 12- and 18-month time points, poor responders still had a 
significantly lower proportion of patients achieving MMR. At 12 months, only two 
patients out of 11 (18%) achieved MMR versus 25 out of 39 (64%) in the 
responders group (p<0.01; Figure 10 A). The result did not differ greatly at 18 
months, as three patients out of 11 (27%) achieved MMR in the poor responders 
group versus 27 out of 36 (75%) in the responders group (p<0.01; Figure 10 B). 
BCR-ABL1 levels were also higher in poor responders (0.5%) than in the 
responders group (0.03%) at 12 months (p<0.05; Figure 10 C) and 18 months 
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(0.2% and 0.02% for poor responders and responders, respectively; p=ns; Figure 
10 D). 
p < 0 .0 1
R e s p o n d e rs P o o r
re s p o n d e rs
0
2 0
4 0
6 0
8 0
1 0 0
%
18
36
64
82
0 .0 07
R e s p o n d e rs P o o r
re s p o n d e rs
0
2 0
4 0
6 0
8 0
1 0 0
%
27
25
75
73
0 .0 04
p < 0 .0 1
n o M M R
M M R
B
C
R
-A
B
L
1
%
R e s p o n d e rs P o o r
re s p o n d e rs
-0 .5
0 .0
0 .5
1 .0
1 .5
2 .0
4 .0
4 .2
4 .4
4 .6
4 .8
5 .0 0.0367 p < 0 .0 5
B
C
R
-A
B
L
1
%
R e s p o n d e rs P o o r
re s p o n d e rs
0
2
4
6
8
0.6840 p = n s
A B
C D
p< 0 .0 1 p < 0 .0 1
p < 0 .0 5 p = n s
1 2 m on th s 1 8 m on th s
1 2 m on th s 1 8 m on th s
 
Figure 10. Poor responders had inferior long-term outcomes compared to 
responders. A, B) Poor responders’ achievement of MMR was low at 12 and 18 
months when compared to responders. C, D) BCR-ABL1 median levels of poor 
responders were higher than that of responders ns=not significant. 
 
The ELN 12-month time point recommendations for first line TKI therapy 
responses are presented in Table 5. Out of the 11 poor responder cases in our 
study, only two (18%) were able to reach the ELN-described optimal response, six 
cases (54%) belonged to the warning group, and three (27%) cases had a failure 
response. On the other side, 26 out of the total of 41 responders (65%) had an 
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optimal response, nine (22.5%) belonged to the warning group, and only five 
(12.5%) showed a failure response (p<0.05; Figure 11). 
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Figure 11. The poor responders group had more failure cases according to 
ELN recommendations at 12 months, while the responders group had more 
optimal response cases.4 
 
17.3.3. Long-term therapy outcomes were less satisfactory for poor responders  
In the 24-month follow-up, we found that only six (54.4%) out of the 11 poor 
responder cases achieved MMR versus 27 out of the 31 responder cases (87.1%, 
p=0.02). For the 36-month follow-up, only seven (70%) out of the 10 poor 
responders achieved MMR versus 27 out of 31 responders (87.1%) 
 
18. Early BM lymphocytosis with TKI is accompanied by better response (II)  
18.1. TKI therapy induces BM lymphocytosis 
The proportion of BM lymphocytes was significantly lower in patients at dg when 
compared to healthy controls (3% vs.12%; p<0.0001; Figure 12 A).  
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Figure 12. Percentage of BM lymphocytes significantly increased and 
remained elevated during TKI therapy. A) BM lymphocyte percentages for 
patients at dg (3%) were significantly lower than those in healthy controls (12%) 
(p<0.0001). B) BM lymphocyte percentage was low at dg (0 months) but was 
elevated at further time points (3, 6, 12, and 18 months). Elevation was significant 
for all the three drugs analyzed C) Changes in relative PB lymphocyte counts at dg 
and 3, 6, 12, and 18 months. D) PB lymphocytes numbers at dg and 3, 6, 12, and 18 
months. The curves show median lymphocytes at different time points, while the 
dotted lines show median normal values (12%) in graph B and the upper and lower 
limit normal values in graphs C and D.  
 
 At the 3-month time point after starting TKI therapy, a significant BM lymphocyte 
expansion occurred. The lymphocyte percentage was 20% for TKI treated patients 
versus 12% for the controls (Figure 13). 
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Figure 13. Increased proportion of BM lymphocytes at 3 months after TKI 
start. The percentage of lymphocytes after 3 months of TKI administration was 
significantly elevated when compared to healthy controls (p<0.0001). 
 
When comparing the different drugs, we found that the 3-month BM 
lymphocytosis occurred during treatment with both the first-generation TKI 
imatinib as well as with the second-generation TKIs dasatinib and nilotinib. The 
lymphocyte percentages were 20%, 21%, and 22% for imatinib, dasatinib and 
nilotinib treated patients, respectively (Figures 12 B and 14). The 6-, 12-, and 18-
month time points also showed a plateau or slight regression in lymphocyte 
percentages with no significant differences between the drugs (Figure 12 B).  
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Figure 14. Individual TKIs did not show differences regarding BM 
lymphocyte percentages. We compared individual TKIs with healthy controls. No 
differences were observed among the different TKIs, but all had higher percentages 
of BM lymphocytes when compared to healthy controls.  ns=not significant; 
**p<0.01; ***p<0.001. 
 
Also PB lymphocyte percentages increased at 3 months (Figure 12 C). Conversely, 
absolute PB lymphocyte counts were significantly higher at dg before TKI 
treatment and showed regression to normal levels during the TKI administration. 
However, a reduction in absolute lymphocyte counts (Figure 12 D) was observed 
due to TKI.(as TKIs reduce leukocytosis that result due to CML myeloid 
proliferation) .  
Sokal scores were significantly associated with BM lymphocyte counts. The 
patients with lower Sokal scores had elevated BM lymphocyte percentages at 3 
months (26%, range 5–38%) when compared to those with high Sokal scores (18%, 
range 7–33%; p<0.05; Figure 15). 
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Figure 15. The Sokal score is associated with the higher lymphocytic 
percentage at 3 months. Patients with low Sokal scores have higher BM 
lymphocytes at 3 months than patients with high Sokal scores (*p<0.05).  
 
18.2. Early BM lymphocytosis is associated with favorable molecular responses 
We found that the BM lymphocyte percentage at 3 months was significantly higher 
in patients with an early optimal ELN 3-month molecular response (BCR-ABL1 
levels ≤10%). Namely, percentage of BM lymphocytes was 23% in patients with 
BCR-ABL1 levels ≤10% vs. 17% in those with BCR-ABL1 levels >10%; p<0.05 
(Figure 16). 
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Figure 16. The BM lymphocyte percentage was significantly higher in patients 
with an early 3-month molecular response (p<0.05). 
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In patients reaching an optimal or a warning ELN response, BM lymphocytes 
formed 19.5% and 28.5% of BM cells, respectively, whereas the percentage was 
12% in the control group (p<0.01 between controls versus optimal; p<0.0001 
between controls versus warning; pANOVA<0.0001; Figure 17). All failure 
patients were in hematological remission. There was a large individual variation in 
their BM lymphocyte counts, the median lymphocyte count being 18.5%, that was 
not significantly different from the controls. Interestingly, the warning group had a 
higher lymphocyte percentage than the optimal (p<0.05) and the failure (p<0.05) 
groups. We were not able to analyze treatment responses between different TKIs 
due to a low number of patients with second-generation TKIs.  
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Figure 17. Three-month BM lymphocytosis compared to the ELN 
recommendation for 12-month response classification. Different ELN groups 
showed different BM lymphocytic counts. ns=not significant; *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001. 
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19. Dasatinib-treated patients had more cytotoxic lymphocytes (II) 
We performed flow cytometric analyses to determine the composition of the 
increased BM lymphocyte populations.  
19.1 TKI treatment is accompanied by an increase in n-terminal kinase (NK) cells 
We found that NK cells were increased in BM after treatment with TKIs. At the 3-
month time point the proportion of NK cells was 19.4% of marrow lymphocytes as 
compared to 16.8% at dg (p<0.05; Figure 18 A). Similarly, an increase in PB NK 
cells was also observed. The proportion of NK cells of all PB lymphocytes at 3 
months was 22% as compared to 15.7% at dg ( p<0.01; Figure 18 B). 
 
Figure 18. The proportion of NK cells were significantly elevated at the 3-
month time point in both BM (*p<0.05) and PB (**p<0.01). ns=not significant. 
 
19.2 Dasatinib-treated patients had an increase in T-cells with a cytotoxic 
phenotype and a decrease in Tregs 
As only limited data is available on the in vivo immunological effects of second 
generation TKI treatments, we compared the effects of the three TKIs on the 
lymphocyte phenotypes. Although the samples were small (12, 7, and 6 patients 
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treated with imatinib, dasatinib, and nilotinib, respectively), we still aimed to 
analyze them. The analyses were done at the 3- and 6-month time points, but only 
the results of the 6-month time point are presented here due to the larger number of 
available samples. The proportions of different lymphocyte subsets were examined 
in both the BM and the PB cells.  The number of CD3+ T-cells and CD3-
CD16/56+ NK cells did not vary between the three different TKI treatments. 
However, the patients treated with dasatinib were found to have significantly more 
BM and PB CD8+ T cells than the patients treated with imatinib and nilotinib. 
Namely, the BM CD8+ T-cells formed 51%, 39%, and 33% of all the lymphocytes 
in the patients treated with dasatinib, imatinib, and nilotinib, respectively (Figure 
19 A). In the PB samples, the CD8+ cells were also significantly higher in the 
patients treated with dasatinib  (45% of the lymphocytes) in comparison to the 
patients treated with imatinib and nilotinib (31% and 29% of lymphocytes, 
respectively) (Figure 19 B). The patients treated with dasatinib had lower BM 
Tregs (3.2%) than the patients treated with imatinib (5.7%, p<0.05). In the patients 
treated with nilotinib, the percentage of Tregs (5%) was similar to both the values 
of the patients treated with imatinib and the values before the treatment (5.1%) 
(Figure 19CD). 
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Figure 19. The T-cell immunophenotype is shifted toward the cytotoxic T-cell 
phenotype and low Tregs in dasatinib patients. A–B) CD8+ T-cells are 
significantly increased both in BM and PB in dasatinib treated patients when 
compared to imatinib treated patients. C–D) Tregs in BM are significantly lower in 
dasatinib treated patients when compared to those treated with imatinib. *p<0.05; 
**p<0.01; ***p<0.001 
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The increased CD8+ T cells in dasatinib patients showed higher HLA-DR and 
lower CD62L expression when compared to those observed in imatinib and 
nilotinib treated patients. (Table 10)   
Table 10. Six-month HLA-DR and CD62L expression in CD8+ T cells in CML 
patients treated with TKIs. 
CD8HLA-DR 
  BM PB 
  Dasatinib Imatinib Nilotinib Dasatinib Imatinib Nilotinib 
cases (n*) 7 12 6 8 12 7 
Median 41% 22% 15% 34% 12% 13% 
(minimum-
maximum) 
(5.5%–
53%) 
(8%–
54%) 
(7%–
29%) 
(6%–
58%) 
(4%–
40%) 
(12%–
35%) 
  Ns   p<0.05   
    p<0.01   p<0.05 
CD8CD62L 
  BM PB 
  Dasatinib Imatinib Nilotinib Dasatinib Imatinib Nilotinib 
cases (n*) 7 12 6 8 12 7 
Median 23% 46% 38% 37% 62% 50% 
(minimum-
maximum) 
(9%–
37%) 
(15%–
68% 
(18%–
68%) 
(15%–
55%) 
(16%–
84%) 
(37%–
79%) 
  p<0.01   p<0.01   
n*=number of cases; 
ns=not significant 
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20. TKI treatment affects humoral immunity (III)  
20.1. B cell counts decrease in PB during TKI therapy 
The percentage of B-cells in the BM samples was lower in the CML patients at 
diagnosis in comparison to the healthy controls (9.9%, range 1.3–18.3 versus 
17.5%, range 12.2–23; p<0.01). A slight increase at the 3-month time point was 
observed (median 11.8%, range 1.2–25.4) in comparison to the values at diagnosis 
(9.9%, range 1.3–18.3; p<0.05). However, the BM B-cell counts of the CML 
patients remained lower than the BM B-cell counts of the healthy controls during 
the follow-up (pANOVA=ns; Figure 20 C).  
Both the relative and absolute number of PB B-cells decreased after the start of 
TKI therapy. The median percentage of the PB B-cells at 1-month post-TKI was 
5.7% (range 0.27–11%) versus 10% (1.4–23.5%) at diagnosis (p<0.001; Figure 20 
A). One-month post-TKI treatment, the median absolute counts decreased to 0.04 
x109/L (range 0.005–0.2 x109/L) in comparison to the value at diagnosis, which 
was 0.3 x109/L (range 0.078–1 x109/L) ( p<0.001; Figure 20 B). This decrease in 
the number of PB B-cells improved slightly over time (Figure 20 A, B). The PB B-
cell counts were not significantly different from the counts for the healthy controls 
(p=ns for both absolute and relative PB B-cells at diagnosis versus the healthy 
controls).  The BM-B cell counts were significantly lower in the CML patients than 
the healthy controls (**p<0.01). TKI therapy induced an increase in the B-cell 
count at the 3-month follow-up in comparison to the count at diagnosis (*p<0.05 
between diagnosis and the 3-month time point).No significant differences were 
observed between the B-cell counts for the three different TKIs (Figure 20 D). 
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Figure 20. PB B cells decrease during TKI treatment. A–B) Relative and 
absolute PB cells at dg were comparable to those of controls (p=ns). Relative and 
absolute PB cells were decreased after 1 month of TKI therapy (*p<0.001 for 
both), and the observed decrease persisted also in later time points (pANOVA 
<0.01 and <0.0001 for relative and absolute B cells, respectively). C) BM B cells 
were significantly lower than in healthy controls (**p<0.01). After TKI therapy, an 
increase in B cells at 3 months was observed when compared to dg (*p<0.05 
between dg and the 3-month time point).  D) There were no significant differences 
between TKIs with regard to the observed decline in PB B cell counts during the 
treatment. ns=not significant. 
 
In study II, we made the same observation as in study III: The BM B cells were 
initially increased at the 3-month time point (median 10.7%, range 1.3–25.9%) 
when compared to dg (8.6, 1.3–18.1%; p<0.05). However, during the long-term 
follow-up, the increase through 12 months was not significant (pANOVA=ns; 
Figure 21 A). The PB B cells in study II was confirming  the results of study III, 
showing a decrease after treatment (median PB B cell percentage at 3 months was 
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5.9% [range 0.6–18.7%] versus 9% at dg [1.3–23%]; p<0.001), and the recorded 
decrease continued in follow-ups (pANOVA<0.01; Figure 21 B). 
 
Figure 21. In study II, B cells were significantly decreased at the 3-month time 
point in PB (***p<0.001) but elevated in BM (*p<0.05). ns=not significant. 
 
20.2. Plasma immunoglobulin levels decreased during TKI treatment 
 We studied the plasma Ig levels in patients treated with TKIs to obtain more 
information relating to the effects on humoral immunity.  
We found that the median Ig levels of patients at dg did not differ from those of 
healthy controls (IgA 1.40 g/l vs. 1.46 g/l, p=0.7; IgG 8.71 g/l vs. 8.60 g/l, p=0.34; 
IgM 0.93 g/l vs. 0.80 g/l, p=ns). However, in the imatinib-treated patients IgA and 
IgG concentrations significantly decreased during therapy (p<0.05 for both IgA and 
IgG; Figure 22 AB). Similarly, IgM levels decreased in dasatinib-treated patients 
during the follow-up (p<0.01, Figure 22 C). Nilotinib did not have notable effects 
on plasma Ig levels. In bosutinib patients, we observed a small decrease in IgM 
levels, but due to the small number of patients, it was not significant. When 
individual TKIs were compared to each other, patients in the imatinib group had 
the lowest levels of IgA and IgG, whereas dasatinib-treated patients had the lowest 
IgM levels. (Figure 22 D–F). 
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Figure 22. TKI treatment is associated with a decrease in Ig levels. A–C) 
Patients on imatinib showed a significant decrease in IgA and IgG (p<0.05 for 
both), while those on dasatinib had a significant IgM decrease (p<0.01). D–F) In 
individual TKI comparisons, IgA was significantly decreased in imatinib when 
compared to other TKIs (p<0.0001), while IgG and IgM showed no differences.  
ns=not significant; *p<0.05. 
 
20.3. Imatinib-treated patients had more immature B cells 
A more detailed phenotyping for B cells was done with flow cytometry. The 
mature BM CD19+ B cells were significantly lower in imatinib- compared to 
dasatinib-treated patients (median at 3 months was 49% vs. 85%; p<0.01). The 
proportion of maturing B cells was much higher in imatinib- compared to 
dasatinib-treated patients and controls (median 38% in imatinib versus 9.4% in 
dasatinib and 24.5% in controls; p<0.01 and <0.05 for the difference between 
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imatinib versus dasatinib and controls, respectively; Figure 20.4 B). Similar to the 
results for maturing B cells, imatinib patients also had the highest proportion of 
immature BM CD19+ B cells versus dasatinib and controls (median=8.2% versus 
4.8% and 2%, respectively), and the difference between immature B cells with 
imatinib and dasatinib was significant (p<0.001; Figure 23 A–C). The B cell profile 
during nilotinib therapy was similar to that of imatinib patients.  
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Figure 23. Imatinib-treated 
patients showed a significant 
decrease in mature B cells but an 
increase in maturing and 
immature B cells. A) At 3 months, 
imatinib-treated patients had 
significantly fewer mature B cells 
than those taking dasatinib. B) At 3 
months, imatinib-treated patients had 
significantly more maturing B cells 
than both dasatinib-treated patients 
and controls. C) At 3 months, 
imatinib-treated patients had 
significantly more immature B cells 
than those taking dasatinib.  
*p<0.05; **p<0.01; ***p<0.001. 
 
 
We also analyzed other B cell subpopulations in PB and found no significant 
differences regarding naive, memory, plasmablasts, and transitional B cells when 
compared to healthy controls. Hypogammaglobulinemia during follow-up did not 
correlate with PB B cell subpopulations. 
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20.4 Low Ig levels can predict hypogammaglobulinemia during treatment  
When comparing the patient group with hypogammaglobulinemia (defined as an Ig 
concentration at least 2 standard deviation below the lower limit of normal) to that 
without the condition, we found that the group with hypogammaglobinemia had 
significantly decreased Ig levels already at dg (IgG, p<0.01; IgM, p<0.01; IgA, 
p=ns; Figure 24 A–C) as well as during follow-ups (IgA, p=0.0008; IgG, p<0.0001; 
IgM, p<0.0001; Figure 24 D–F). However, the median Ig subclass values in the 
hypogammaglobinemia group were still within the normal range for all the 3 Ig 
subclasses (median values for IgA =1.3 g/l [normal 0.52–4.84 g/l], IgG = 8.05 g/l 
[6.8–15 g/l], IgM=0.65 g/l [0.36–2.84 g/l]; Figures 24 A–C). 
 
70 
 
A
B
C
IgA at d iagnos is
N o h y p o g am m a H yp o g am m a
0
1
2
3
4
5
p =ns
g
/l
IgG a t d iagnos is
N o h y p o g am m a H yp o g am m a
0
5
1 0
1 5
2 0
p <0 .0 1
g
/l
IgM at d iagnos is
N o h y p o g am m a H yp o g am m a
0
1
2
3
4
p <0 .0 1
g
/l
IgA fo llow -up
0 3 6 9 1 2 1 5 1 8 2 1 2 4
0
1
2
3
4
5
6 N o h yp o g am m a
H y p o g am m a
M on th
g
/l
IgM fo llow -up
0 3 6 9 1 2 1 5 1 8 2 1 2 4
0
1
2
3
4 N o h yp o g am m a
H y p o g am m a
M on th
g
/l
IgG fo llow -up
0 3 6 9 1 2 1 5 1 8 2 1 2 4
0
2
4
6
8
1 0
1 2
1 4
1 6
1 8
2 0 N o h yp o g am m a
H y p o g am m a
M on th
g
/l
D
E
F
p = 0 .0 0 0 8
p < 0 .0 0 0 1
p < 0 .0 0 0 1
 
Figure 24. Patients with hypogammaglobulinemia had decreased Ig levels 
before treatment (A–C), and this predisposed them to 
hypogammaglobulinemia during TKI treatment (D–F). ns=not significant 
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20.5. No severe infections were reported in our cohort  
Despite the low Ig levels, we found no severe or major infections in our patients. 
Only minor infections were reported in eight of the 24 cases with low Ig levels. In 
patients with normal Ig levels, infections were reported more rarely (only 1 out of 
34 cases). Reported infections can be seen in Table 11. 
Table 11. Infections in patients with hypogammaglobulinemia. 
Case First-line TKI Infections Decreased Ig (onset of decrease) 
1 Imatinib Sinusitis and bronchitis 
IgA (at 3 months) 
IgG (at 3 months) 
IgM (at 6 months) 
2 Imatinib Conjunctivitis and common cold IgG (at diagnosis) 
3 Dasatinib Conjunctivitis IgG (at 12 months) IgM (at 6 months) 
4 Dasatinib E-coli cystitis IgM (at diagnosis) 
5 Nilotinib Common cold and oral HSV IgG (at diagnosis) 
6 Nilotinib Common cold and oral HSV IgM (at diagnosis) 
7 Nilotinib Gastroenteritis and skin boil IgG (at 3 months) 
8 Bosutinib Common cold IgM (at 3 months) 
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DISCUSSION 
One-month in vivo TKI response defines a group of patients with inferior 
long-term outcomes. 
TKIs are generally known to induce fast responses in patients, and therefore we 
hypothesized in study I that that the response prediction can be done a mere 1 
month after starting the treatment with a TKI. We defined our prediction through 
comparing the change in BCR-ABL1 levels between the diagnostic level and the 1-
month time point. We distinguished a group of poor responders, who failed to 
achieve a decrease in BCR-ABL1 transcript levels during 1 month of therapy. This 
group of poor responders not only had slower response rates but also failed to 
reach optimal responses at later time points. The poor response was not related to 
TKI type, as it was observed among both first- and second-generation TKI 
treatments. 
Several studies have proposed different methods and criteria to detect early 
responses for CP CML. Typically, 3 months has been regarded as the earliest 
predictive time point. The 3-month point in current treatment algorithms states that 
BCR-ABL1 levels less than 10% will be a sign of optimal response.4,47,65–68 
However, our study has another advantage over the classification relating to BCR-
ABL1 levels less than 10%, as it considers individual variations in initial BCR-
ABL1 transcript levels. The initial BCR-ABL1 level is known to be different 
between patients65,69, and taking individual declines in the BCR-ABL1 levels into 
account is more informative than having a general cutoff point of 10%. Hanfstein 
and colleagues have suggested a half-log reduction in BCR-ABL1/GUS levels 
during the first 3 months as a differentiator between good and poor responses. 
Patients who reached the half-log reduction were responding optimally, and those 
who failed to reach it were at risk of CML progression.65 Similarly, Branford et al 
73 
 
have shown that the early 3-month decline could be a critical prognostic factor 
when aiming to identify poorly responding patients.70 
It is important to recognize poor responders in CP CML as early as possible to 
avoid the progression to more advanced disease phases, which have higher 
incidence rates during the first year of TKI therapy. With early prediction, there is a 
better chance of implementing treatment modifications. Accordingly, prediction of 
response as early as 1 month can strongly affect patients’ later outcomes. Among 
our patients in study I, we found that one fifth (21%) failed to have any decrease of 
BCR-ABL1 levels after 1 month of TKI therapy. Importantly, we checked drug 
accountability logs used for the clinical trial records to verify that the patients had 
regularly taken all the prescribed TKI doses; as a result, it can be concluded that the 
poor response status is due to the disease itself and not poor compliance from 
patients. 
We compared our classification to the cutoff of 3-month BCR-ABL1 levels of less 
than 10% that is recommended by several studies.4,47,65,68 It is noteworthy that all 
the responders in our study were able to achieve optimal responses (BCR-ABL1 
levels <10%), while 36% of our poor responders could not reach BCR-ABL1 
levels less than 10%. At the later time points, and according to the 12-month ELN 
recommendation, 80% of our poor responders were not able to achieve MMR at 12 
months, and their responses were regarded as warning or failure.4 Similarly, for the 
18-month follow-up, 73% of poor responders were still not able to achieve MMR. 
The responses were not related to the TKI therapy type, because imatinib and 
dasatinib were represented equally in our study patients. There were no nilotinib 
patients in the poor responders group, which may be due to the low number of 
nilotinib cases in our study (only 5 cases). Despite the changing treatment 
protocols, 36% of poor responder cases still had inferior treatment outcomes at the 
24- and 36-month time points. This confirms that poor responders are more prone 
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to an inferior long-term prognosis. However, it should be noted that none of the 
patients in the poor responder group progressed in our study, and thus the relation 
of 1-month outcomes to progression and overall survival needs to be considered in 
longer clinical trials. 
Poor responders have specific biological characters at dg 
The above findings suggest that these poor responders have a different disease 
pathology than responders. Contrary to our expectations, initial BCR-ABL1 levels 
were lower in poor responders. Age, sex, WBC, blasts, and basophils showed no 
differences between poor responders and responders. Despite advancements in 
CML evaluation and dg, the spleen remains an important clinical parameter for 
CML evaluation, dg, and staging. Spleen size is used in all up-to-date staging 
systems for CML (the Sokal, EUTOS, and EURO scores).25–27 We found that 
splenomegaly was common among poor responders, as more than half of poor 
responders had palpable spleen at dg in comparison to less than 15% of 
responders. In combination with splenomegaly, we also observed higher 
percentages of Ph+CD34+CD38- stem cells in BM at diagnosis in poor responders. 
Lower hemoglobin at dg was also observed in poor responders compared to 
responders. These three factors together suggest that the cause for poor response is 
an initial high tumor load at dg. In addition to signaling a higher tumor burden, the 
enlarged spleen as well as high Ph+CD34+CD38- cells in poor responders may 
also be due to other biological aspects of CML. They could mirror, for example, 
signaling pathways that current TKI treatment cannot inhibit, as we found that 
more than half of poor responders were on the second-generation TKI dasatinib, 
which is more potent than the first-generation imatinib. It is of note that the 
Ph+CD34+CD38+ progenitor cells, known to be rapidly dividing and so expected 
to be quickly eradicated by TKI therapy, were very slowly eliminated in the poor 
responders group. This can suggest that increased BCR-ABL1 levels in these poor 
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responder cases reflect the low capability of the TKI treatment used to decrease 
this cell population in these patients. Previous studies denoted that BCR-ABL1 
levels in the CML Ph+CD34+ stem cells reflects the tumor load of CML, disease 
severity, and drug response.9,13–15,71 
 
Early BM lymphocytosis is associated with good TKI treatment outcomes. 
It has previously been shown that imatinib-induced BM lymphocytosis in a small 
patient cohort.21 In our study II, we relied on a larger cohort of 105 patients to 
confirm this phenomenon in the first-generation imatinib as well as the second-
generation TKIs dasatinib and nilotinib.  
Due to myeloid expansion caused by CML, the proportion of BM lymphocytes is 
normally reduced at dg. After a hematological remission that usually occurs shortly 
after TKI therapy due to treatment-induced eradication of leukemia cells, it is 
expected that the BM lymphocytes will be increased when compared to diagnostic 
values. However, we found that BM lymphocytes at 3 months showed significantly 
higher percentages than the normal values of healthy controls. In addition, BM 
lymphocytosis persisted, with no decrease during longer follow-up time points after 
TKI eradication of leukemic myeloid cells when there were no more Ph+ cells 
detected in BM through both cytogenetic and molecular measure. Furthermore, BM 
aspirates were normocellular, suggesting that the relative increase in lymphocytes 
is not due to hypoplastic conditions in which myeloid cells are diminished. PB 
lymphocytes did not increase during either imatinib or nilotinib therapy, but they 
increased during dasatinib treatment, as previously reported.31,37,72 This suggests 
that the mechanism of lymphocytosis in BM and PB is different. The dasatinib 
lymphocytosis in PB may be explained by the mobilization phenomenon that is 
confined to dasatinib treatment.37 
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Furthermore, in study II, we compared this early BM lymphocytosis phenomenon 
to the currently established treatment response classification and 
recommendations.4,24,47,65,68 We found that patients who had lymphocytosis 
achieved optimal response rates at the 3-month time point (BCR-ABL1 levels 
<10%) significantly more often. At the 12-month response time point, and 
according to the 12-month ELN classification, BM lymphocytes were increased in 
cases with optimal response (MMR at 12 months), while cases with failure showed 
no significant increase compared to healthy controls. Interestingly, cases that were 
classified by the ELN 12-month recommendation as warning had the highest BM 
lymphocytic counts. It is possible that this could be explained by a lack of immune 
homeostasis due to immune reactivity in this warning group, which was neither 
able to achieve the optimal response nor progressed to failure. However, further 
studies are needed to clarify whether BM lymphocytosis can be an independent 
prognostic factor. 
Dasatinib treatment showed a shift toward cytotoxic phenotype and decreased 
Tregs  
Immunophenotyping results by flow cytometry demonstrated that dasatinib patients 
had a unique lymphocytic subpopulation composition that was shifted in the 
cytotoxic direction, which was not found in the imatinib or nilotinib groups. The 
CD8+ T cells in BM as well as in PB were significantly increased. CD8+ T cells 
have a killing capacity and thus can contribute to a decrease in tumor load.73,74 This 
CD8+ T cell increase was also accompanied by an increase in the activation marker 
HLA-DR. These results were in accordance with our previous results regarding 
dasatinib-induced LGL lymphoctytosis.31,36,75 CD62L, expressed on cytotoxic 
CD8+ T cells during dasatinib therapy, has been described as a marker for TKI 
therapy discontinuation.76 Decrease in the Tregs was also solely confined to the 
BM of dasatinib-treated patients, and it was not observed in imatinib or nilotinib 
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patients. The Treg decrease during dasatinib therapy has also been previously 
reported, but those patients were not receiving first-line treatment.77,78 The decrease 
of Treg is desirable in CML, as Tregs can induce tolerance of the immune system 
toward the tumor.73,79–81 
To date, no studies have addressed BM immunophenotyping during nilotinib 
treatment. In our small cohort of nilotinib-treated patients, we found that they had 
similar lymphocytic subclasses (B, T, NK and Tregs) to imatinib-treated patients. 
A previous in vitro study had demonstrated a suppressive effect of nilotinib on 
Tregs, but it was not possible to observe any differences in amount of Tregs. The 
doses used in the in vitro study may not be clinically relevant.82 
No severe infections were observed, despite low Ig levels and a decrease in B 
cells during TKI therapy. 
In studies II and III, we found that despite an increase in BM B cells after TKI 
therapy, these values were always lower than in healthy controls. Moreover, we 
discovered a drop in PB B cells after TKI administration. The drop was significant 
both in relative percentages and absolute counts, and it was observed in all 
examined TKIs (namely, imatinib, dasatinib, and nilotinib). Several studies have 
also noted the inhibitory effect of TKIs on B cell lineage.83–85 In addition, several 
studies have suggested that dasatinib is associated with a decrease in B cells.21,83–85 
TKIs are known to inhibit B cell function through binding to the off-target TKs in 
B cells’ development signaling pathways. Specifically, dasatinib was reported to 
have the highest off-target activity on the B cell pathway.52 This raises a question 
as to what extent TKI therapy can affect the humoral immunity of patients and 
whether this can increase the risk of infections. 
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Immunoglobulin levels decrease during TKI therapy 
We compared the effects of four different first-line TKIs (namely, imatinib, 
dasatinib, nilotinib, and bosutinib) on B cells and Ig levels in CP CML. Ig levels at 
dg in CP CML patients were similar to healthy controls. However, decreased Ig 
levels at dg predicted hypogammaglobulinemia with TKI therapy. Only treatment 
with imatinib and dasatinib showed a significant decrease in Ig levels that persisted 
during follow-up. Imatinib in particular was associated with decrease in IgA and 
IgG, while dasatinib showed decreased IgM. In addition, a trend of lower IgM 
levels was observed in bosutinib patients, but the number of patients in our study 
was very small. Our results are in accordance with previous studies on TKIs and Ig 
levels in which patients showed a significant reduction of Ig levels during imatinib 
second-line treatment after interferon-α intolerance.86 Another study with first-line 
imatinib patients showed that 10% of patients had severe 
hypogammaglobulinemia.87 A study of influenza-vaccinated CML patients also 
reported a decrease in IgM titer in CML patients treated with imatinib, dasatinib, 
and nilotinib when compared to healthy control titers.83 Other studies showed a 
clear effect of dasatinib in reducing IgM.56,85  
Imatinib patients, with low IgA and IgG levels, also had significantly more 
immature B cells and fewer mature B cells than dasatinib patients. Mature B cells 
are the cells capable of secreting Ig.88 This low mature B cell percentage may 
explain the imatinib-induced decrease in IgA and IgG. The decreased immature B 
cells and IgM levels in dasatinib that was observed in this study have also been 
previously attributed to dasatinib’s inhibitory effects on immature IgM-secreting B 
cells. Dasatinib tends to target and inhibit immature rather than mature B cell 
lineages.85  
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Decreased Ig levels with TKI treatment do not cause severe forms of infections.  
It seemed that hypogammaglobulinemia contributed to a degree of immune 
impairment among the patients in our study. Cases that showed infections and 
recurrent infections during the TKI treatment were associated with 
hypogammaglobulinemia. However, we did not see severe or major forms of 
infections. A previous study on imatinib showed similar results; there were no 
cases with major infection reported with imatinib-induced 
hypogammaglobinemia.87 It should be noted, however, that one of our imatinib 
patients developed total hypogammaglobulinemia during treatment and 
replacement therapy was needed. Several studies reported an associated risk of 
infection with imatinib, dasatinib, and nilotinib treatment but a low incidence of 
severe or fatal infections.52 Most commonly, these BCR-ABL1 TKIs were 
associated with neutropenia, UTI, and infection reactivation (e.g., HSV, CMV, and 
HBV).52,59,89 The data on nilotinib-associated infections is still insufficient, but 
studies have reported low infection co-morbidities.52,58,90 The data for bosutinib 
comes from a shorter time period and is also still not well defined; however, one 
study reported an increase in URTIs in comparison to imatinib.60 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
The results obtained in this PhD thesis suggest that we can predict the treatment 
outcomes of TKI therapy as early as the 1-month time point. The patients who are 
not able to achieve a decline of BCR-ABL1 levels in the first month may have 
either a higher tumor burden or different biological background in their CML 
disease. Thus, if no in vivo response is achieved during the first month of therapy, 
it could be considered as a warning sign, and therapy modifications may be needed. 
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In the future, it is important to confirm the clinical importance of the 1-month 
therapy response in larger clinical trials. In comparison to the 3-month time point 
of the current treatment guidelines, 1 month offers an earlier option for optimal 
drug modifications and avoidance of poor prognosis, or longer treatment times or 
relapses. Furthermore, as early treatment response seems to relate to a different 
biological background of CML, it would be important to discover novel agents that 
could better target leukemic cells in these patients. 
In addition to direct oncokinase inhibition, all the current TKIs used in the first-line 
therapy of CML induce BM lymphocytosis that persists for a long time with the 
treatment. This phenomenon is accompanied by early molecular responses. 
Dasatinib is unique in having PB lymphocytosis, lower BM Tregs, and a clearer 
cytotoxic T cell phenotype. No major immunophenotypic differences were 
observed during nilotinib therapy. In addition to effects on T cells, TKI treatment 
seems to modulate the humoral B cell responses. This is observed as 
hypogammaglobulinemia, and it is particularly likely to occur during imatinib 
therapy. Clinically, hypogammaglobulinemia was not associated with major 
problems, but minor recurrent infections were observed more often. Future studies 
are needed to understand in detail why hypogammaglobulinemia occurs especially 
during imatinib treatment and whether that is associated with some specific kinase 
inhibition. As imatinib is still the most common TKI used in CML patients, this 
affects a considerable number of patients, and further studies are needed to judge 
whether hypogammaglobulinemia has clear clinical significance and should be 
considered in the treatment algorithms. 
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